Table 2.

Pediatric hematopoietic stem cell transplant physicians’ willingness to use banked autologous cord blood

Disease*	Alternative stem cell source available	Respondent would perform transplant using banked autologous cord blood
		Yes Number (%)	No Number (%)	Combined† Number (%)
Acute lymphoblastic leukemia in 2nd remission after on-therapy relapse
	Matched sibling	0 (0%)	91 (100%)	N/A‡
	Unrelated bone marrow or cord blood	5 (6%)	85 (94%)	N/A
	No suitable allogeneic stem cell source available	55 (62%)	34 (38%)	N/A
Severe aplastic anemia
Newly diagnosed	Matched sibling	25 (28%)	65 (72%)	N/A
Unsuccessful immunosuppressive therapy	Unrelated bone marrow or cord blood	47 (55%)	38 (45%)	N/A
High-risk neuroblastoma
Adequate autologous cord blood cell dose	Autologous PBSC§ or bone marrow	50 (55%)	38 (42%)	3 (3%)
Inadequate autologous cord blood cell dose **	Autologous PBSC or bone marrow	7 (8%)	61 (67%)	23 (25%)

^*Respondents were asked to indicate their preferred stem cell source for a hypothetical 5 year old child whose cord blood had been stored prophylactically at birth (with adequate cell dose of 4 × 10⁷ nucleated cells/kg recipient weight). The child now presents with the specified potentially transplantable disease.

^†Would choose autologous cord blood combined with available alternative stem cell source

^‡N/A, option not offered

^§PBSC, peripheral blood stem cells

^**<2 × 10⁷ nucleated cells/kg recipient weight